Glucosepane: A poorly understood advanced glycation end product of growing importance for diabetes and its complications

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 1, 2014, Pages 21-32

  Monnier, Vincent M ^a   Sun, Wanjie ^a,b   Sell, David R ^a   Fan, Xingjun ^a   Nemet, Ina ^a   Genuth, Saul ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

carbonyl stress; glycemia; HbA1c; methyglyoxal; nephropathy; neuropathy; retinopathy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ARGININE; CARBONYL DERIVATIVE; GLUCOSE; GLUCOSEPANE; HEMOGLOBIN A1C; LYSINE; UNCLASSIFIED DRUG; WATER;

AMADORI REARRANGEMENT; CARBOHYDRATE ANALYSIS; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIASTEREOISOMER; ELIMINATION REACTION; GLUCOSE BLOOD LEVEL; GLYCATION; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYDROLYSIS; MOLECULAR WEIGHT; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN METABOLISM; REVIEW; TISSUE LEVEL; TURNOVER TIME;

ANIMALS; COLLAGEN TYPE I; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; RISK FACTORS; SKIN; VASCULAR DISEASES;

EID: 84891394604     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0174     Document Type: Review

References (46)

1. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med 1976;295:417-20.
2. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
3. UKPDS33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
4. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003;348: 2294-303.
5. Cleary PA, Orchard TJ, Genuth S, Wong ND, Detrano R, Backlund JY, et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006;55:3556-65.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
7. Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nature Rev Drug Disc 2009;8:417-29.
8. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998;339:69-75.
9. Lederer MO, Buhler HP. Cross-linking of proteins by Maillard processes-characterization and detection of a lysinearginine cross-link derived from D-glucose. Bioorg Med Chem 1999;7:1081-8.
10. Gobert J, Glomb MA. Degradation of glucose: reinvestigation of reactive alpha-dicarbonyl compounds. J Agric Food Chem 2009;57:8591-7.
11. Biemel KM, Lederer MO. Site-specific quantitative evaluation of the protein glycation product N(6)-(2,3-Dihydroxy-5,6-dioxohexyl)-l-lysinate by LC-(ESI)MS peptide mapping: evidence for its key role in AGE formation. Bioconjug Chem 2003;14:619-28.
12. Nakamura K, Hasegawa T, Fukunaga Y, Ienaga K. Crosslines A and B as candidates for the flurophores in age-and diabetesrelated cross-linked proteins, and their diacetates produced by Maillard reaction of alpha-N-acetyl-L-lysine with D-glucose. J Chem Soc Chem Comm 1992:992-4.
13. Aoki S, Hasegawa G, Shigeta H, Obayashi H, Fujii M, Kimura F, et al. Crossline levels in serum and erythrocyte membrane proteins from patients with diabetic nephropathy. Diabetes Res Clin Pract 2000;48:119-25.
14. Nemet I, Strauch CM, Monnier VM. Favored and disfavored pathways of protein crosslinking by glucose: glucose lysine dimer (GLUCOLD) and crossline versus glucosepane. Amino Acids 2011;40:167-81.
15. Nasiri R, Zahedi M, Jamet H, Moosavi-Movahedi AA. Theoretical studies on models of lysine-arginine cross-links derived from alpha-oxoaldehydes: A new mechanism for glucosepane formation. J Mol Model 2012;18:1645-59.
16. Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 2000;6:114-25.
17. Jonas AJ, Lin SN, Conley SB, Schneider JA, Williams JC, Caprioli RC. Urine glyceraldehyde excretion is elevated in the renal Fanconi syndrome. Kidney Int 1989;35:99-104.
18. Sell DR, Biemel KM, Reihl O, Lederer MO, Strauch CM, Monnier VM. Glucosepane is a major protein cross-link of the senescent human extracellular matrix. Relationship with diabetes. J Biol Chem 2005;280:12310-5.
19. Fan X, Sell DR, Zhang J, Nemet I, Theves M, Lu J, et al. Anaerobic vs aerobic pathways of carbonyl and oxidant stress in human lens and skin during aging and in diabetes: A comparative analysis. Free Radic Biol Med 2010;49:847-56.
20. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999;48:870-80.
21. Dammann P, Sell DR, Begall S, Strauch C, Monnier VM. Advanced glycation end-products as markers of aging and longevity in the long-lived Ansell's mole-rat (Fukomys anselli). J Gerontol A Biol Sci Med Sci 2012;67:573-83.
22. Mustata GT, Rosca M, Biemel KM, Reihl O, Smith MA, Viswanathan A, et al. Paradoxical effects of green tea (camellia sinensis) and antioxidant vitamins in diabetic rats: improved retinopathy and renal mitochondrial defects but deterioration of collagen matrix glycoxidation and cross-linking. Diabetes 2005;54:517-26.
23. Biemel KM, Friedl DA, Lederer MO. Identification and quantification of major Maillard cross-links in human serum albumin and lens protein. Evidence for glucosepane as the dominant compound. J Biol Chem 2002;277:24907-15.
24. Verzijl N, DeGroot J, Thorpe SR, Bank RA, Shaw JN, Lyons TJ, et al. Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 2000;275:39027-31.
25. Schnider SL, Kohn RR. Effects of age and diabetes mellitus on the solubility and nonenzymatic glucosylation of human skin collagen. J Clin Invest 1981;67:1630-5.
26. Schnider SL, Kohn RR. Effects of age and diabetes mellitus on the solubility of collagen from human skin, tracheal cartilage and dura mater. Exp Gerontol 1982;17:185-94.
27. Vater CA, Harris ED, Jr., Siegel RC. Native cross-links in collagen fibrils induce resistance to human synovial collagenase. Biochem J 1979;181:639-45.
28. Dai Z, Nemet I, Shen W, Monnier VM. Isolation, purification and characterization of histidino-threosidine, a novel Maillard reaction protein crosslink from threose, lysine and histidine. Arch Biochem Biophys 2007;463:78-88.
29. Watkins NG, Neglia-Fisher CI, Dyer DG, Thorpe SR, Baynes JW. Effect of phosphate on the kinetics and specificity of glycation of protein. J Biol Chem 1987;262:7207-12.
30. Dai Z, Wang B, Sun G, Fan X, Anderson VE, Monnier VM. Identification of glucose-derived cross-linking sites in ribonuclease A. J Proteome Res 2008;7:2756-68.
31. Ahmed MU, Thorpe SR, Baynes JW. Identification of N epsiloncarboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986;261:4889-94.
32. Chetyrkin S, Mathis M, Pedchenko V, Sanchez OA, McDonald WH, Hachey DL, et al. Glucose autoxidation induces functional damage to proteins via modification of critical arginine residues. Biochemistry 2011;50:6102-12.
33. Monnier VM, Sell DR, Dai Z, Nemet I, Collard F, Zhang J. The role of the amadori product in the complications of diabetes. Ann N Y Acad Sci 2008;1126:81-8.
34. Nemet I, Monnier VM. Vitamin C degradation products and pathways in the human lens. J Biol Chem 2011;286:37128-36.
35. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986;232:1629-32.
36. Metz TO, Alderson NL, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: A novel therapy for treatment of diabetic complications. Arch Biochem Biophys 2003;419:41-9.
37. Fan X, Liu X, Potts B, Strauch C, Nemet I, Monnier V. Topical application of L-arginine blocks advanced glycation by ascorbic acid in the lens of hSVCT2 transgenic mice. Mol Vis 2011;17:2221-7.
38. Dobler D, Ahmed N, Song L, Eboigbodin KE, Thornalley PJ. Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. Diabetes 2006;55:1961-9.
39. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003;375:581-92.
40. Monnier VM, Sell DR, Strauch C, Sun W, Lachin JM, Cleary PA, et al. The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. J Diabetes Complications 2013;27:141-9.
41. Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep 2010;10:276-82.
42. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005;54:3103-11.
43. Monnier VM, Sell DR, Genuth S. Glycation products as markers and predictors of the progression of diabetic complications. Ann N Y Acad Sci 2005;1043:567-81.
44. Bos DC, de Ranitz-Greven WL, de Valk HW. Advanced glycation end products, measured as skin autofluorescence and diabetes complications: A systematic review. Diabetes Technol Ther 2011;13:773-9.
45. Lyons TJ, Basu A. Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers. Transl Res 2012;159:303-12.
46. Beisswenger PJ. Glycation and biomarkers of vascular complications of diabetes. Amino Acids 2012;42:1171-83.